CereVasc, Inc., a company focused on improving the treatment of patients with hydrocephalus, announced today the closing of an expanded Series A financing that raised a total of $43.9 million led by the Perceptive Xontogeny Venture (PXV) Fund and ATON Partners, LLC.


CereVasc, Inc. is a medical device company focused on the development of novel, minimally invasive treatments for patients with neurological diseases. The Company’s first product, the eShunt System, is the first minimally invasive cerebrospinal fluid shunt designed to avoid the need for invasive surgery and extended hospitalization associated with the current surgical treatment of hydrocephalus using ventriculo-peritoneal shunts. For more information, visit www.cerevasc.com.

CereVasc Announces Closing of $43.9 Million Series A Financing

Description

Company Information

Related People

Funding Insights